At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
testosterone ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Testosterone 0.03% Ophthalmic Solution Compared to Vehicle for the Treatment of Meibomian Gland Dysfunction
In Brief
A Phase 2 clinical trial evaluating testosterone ophthalmic solution and vehicle of testosterone ophthalmic solution for Meibomian Gland Dysfunction. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedSep 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedSep 18, 2008
Enrollment StartJul 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.8 years ago
Interventions
testosterone ophthalmic solutiondrug
testosterone ophthalmic solution for 128 days
vehicle of testosterone ophthalmic solutiondrug
vehicle of testosterone ophthalmic solution for 128 days